Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide in Erythropoietic Protoporphyria (CUV037)
NCT04578496Phase 3Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jul 2011
- Primary completion
- Feb 2014
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 3 trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Started Jul 2011; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT04578496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578496.